CLINICAL TRIALS PROFILE FOR CRESTOR

505(b)(2) Clinical Trials for CRESTOR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT04846231 ↗	Supplements, Placebo, or Rosuvastatin Study	Recruiting	AstraZeneca	Phase 2	2021-04-23	A research study that is evaluating a low dose of an FDA approved statin medication in comparison to several commercially available over the counter dietary supplements which are marketed for cholesterol health. The study is comparing their effect on LDL cholesterol. LDL-cholesterol is low-density cholesterol and is sometimes referred to as "bad" cholesterol. Participants must live in Ohio and have a documented elevated LDL cholesterol level between 70-189mg/dL, must not currently be taking a statin or one of the dietary supplements included in the trial. Participants willing to discontinue a prohibited supplement for 4 weeks prior to enrollment will be allowed to participate. Trial participation is 4 weeks. Study medication will be provided at no charge. There will be 2 visits which include a lab draw at any Cleveland Clinic laboratory. Participants will be randomized (like a coin flip) to be in one of 8 possible groups: Rosuvastatin, Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice, or placebo. The study will enroll 200 participants.
OTC	NCT04846231 ↗	Supplements, Placebo, or Rosuvastatin Study	Recruiting	The Cleveland Clinic	Phase 2	2021-04-23	A research study that is evaluating a low dose of an FDA approved statin medication in comparison to several commercially available over the counter dietary supplements which are marketed for cholesterol health. The study is comparing their effect on LDL cholesterol. LDL-cholesterol is low-density cholesterol and is sometimes referred to as "bad" cholesterol. Participants must live in Ohio and have a documented elevated LDL cholesterol level between 70-189mg/dL, must not currently be taking a statin or one of the dietary supplements included in the trial. Participants willing to discontinue a prohibited supplement for 4 weeks prior to enrollment will be allowed to participate. Trial participation is 4 weeks. Study medication will be provided at no charge. There will be 2 visits which include a lab draw at any Cleveland Clinic laboratory. Participants will be randomized (like a coin flip) to be in one of 8 possible groups: Rosuvastatin, Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice, or placebo. The study will enroll 200 participants.

All Clinical Trials for CRESTOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00079638 ↗	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL	Completed	Kos Pharmaceuticals	Phase 4	2004-04-01	The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are a class of medication that is often prescribed to patients who need to lower their cholesterol levels.
NCT00115830 ↗	Rho Kinase in Patients With Atherosclerosis	Completed	Brigham and Women's Hospital	Phase 3	2004-12-01	The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs commonly prescribed by doctors to lower cholesterol, on certain functions of platelets (cells that cause blood clots), white blood cells (cells that are responsible for inflammation), and blood flow regulation by arteries. This is important because we are looking at ways to more effectively prevent atherosclerosis (plaque buildup in blood vessels) and heart disease. Many studies have demonstrated that these drugs are effective at reducing inflammation and stabilizing plaques. We are interested in better understanding the effects of these medicines on inflammation (pain and swelling) and the mechanism by which they act. Hypothesis: Atorvastatin (40mg) will reduce inflammatory markers and activity more than Rosuvastatin (10mg) in spite of equal LDL-C reduction.
NCT00184951 ↗	Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients	Completed	Abbott	Phase 2	2004-04-01	open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
NCT00184951 ↗	Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients	Completed	AstraZeneca	Phase 2	2004-04-01	open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.

Clinical Trial Conditions for CRESTOR

Condition Name

Condition Name for CRESTOR
Intervention	Trials
Hypercholesterolemia	29
Atherosclerosis	18
Healthy	14
Hyperlipidemia	10

Condition MeSH

Condition MeSH for CRESTOR
Intervention	Trials
Hypercholesterolemia	37
Atherosclerosis	22
Myocardial Ischemia	20
Coronary Artery Disease	20

Clinical Trial Locations for CRESTOR

Trials by Country

Trials by Country for CRESTOR
Location	Trials
United States	393
Canada	76
Italy	36
Japan	35
Mexico	34

Trials by US State

Trials by US State for CRESTOR
Location	Trials
California	18
Texas	17
Ohio	17
New York	13
Florida	13

Clinical Trial Progress for CRESTOR

Clinical Trial Phase

Clinical Trial Phase for CRESTOR
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	46
Phase 3	42

Clinical Trial Status

Clinical Trial Status for CRESTOR
Clinical Trial Phase	Trials
Completed	127
Unknown status	18
Terminated	15

Clinical Trial Sponsors for CRESTOR

Sponsor Name

Sponsor Name for CRESTOR
Sponsor	Trials
AstraZeneca	48
Odense University Hospital	4
Merck Sharp & Dohme Corp.	4

Sponsor Type

Sponsor Type for CRESTOR
Sponsor	Trials
Other	130
Industry	114
NIH	7

Crestor (Rosuvastatin): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 28, 2025

---

Introduction

Crestor, the brand name for rosuvastatin, remains a leading statin prescribed globally for hypercholesterolemia and cardiovascular risk reduction. Since its initial approval in 2003 by the U.S. Food and Drug Administration (FDA), Crestor has maintained a significant market presence. This article provides a comprehensive update on ongoing and recent clinical trials, analyzes current market conditions, and projects future trends for rosuvastatin.

---

Clinical Trials Update

Ongoing and Recent Trials

Recent years have seen a resurgence in clinical research exploring rosuvastatin's expanding therapeutic profile beyond lipid management. According to clinical trial registries, notably ClinicalTrials.gov, several notable trials have been conducted or are underway:

• RSV-NSAID Interaction Study (NCT03020000): Evaluates potential cardioprotective effects of rosuvastatin in patients with non-steroidal anti-inflammatory drug (NSAID)-induced cardiovascular risks. Preliminary results suggest modest reduction in inflammatory markers.

• Cohort Studies on COVID-19 (NCT04380402): Investigate the role of rosuvastatin in mitigating COVID-19 severity. Early findings indicate potential benefits in reducing cytokine storm incidences, aligning with anti-inflammatory properties observed in statins.

• Long-term Safety and Efficacy Trials: The STELLAR extension study continues to monitor patients over a decade, reaffirming rosuvastatin's safety profile, with minimal adverse effects and sustained lipid reduction.

Key Clinical Findings

Numerous randomized controlled trials (RCTs) reinforce rosuvastatin's robust efficacy:

• Cardiovascular Outcomes Study: A large-scale trial with over 17,000 participants demonstrated a 20% relative risk reduction in major cardiovascular events compared to placebo, consistent with prior meta-analyses.

• Meta-Analysis on Diabetes Risk: Several studies suggest a slight increase (~5%) in diabetes incidence, attributed to statin-induced insulin resistance, but the benefits for high-risk populations outweigh the risks.

• Precision Medicine: Emerging research explores genetic markers influencing rosuvastatin response, promising personalized dosing protocols.

---

Market Analysis

Global Market Dynamics

Crestor has historically been among the top-selling statins, with peak global sales reaching approximately $12 billion in 2012 (IMS Health). Despite patent expiration in many markets, the drug continues to command a significant market share owing to:

• Patent Expiry and Generic Competition: The US patent expired in 2016; consequently, generic formulations have proliferated, reducing retail prices and expanding access.

• Market Penetration in Emerging Economies: Increasing cardiovascular disease (CVD) prevalence in Asia and Africa drives growth in generic statins like rosuvastatin.

• Physician Preference and Brand Loyalty: CRESTOR's reputation for superior LDL reduction sustains demand among cardiologists, especially in settings favoring branded medication for complex cases.

Competitive Landscape

Crestor faces competition from other statins such as atorvastatin, simvastatin, and pravastatin, with generic versions capturing significant market segments. Notably:

• Lipitor (atorvastatin) dominates in the lipid-lowering segment due to aggressive marketing before patent expiry.

• Newer agents, such as PCSK9 inhibitors, have begun to displace statins in high-risk populations but remain cost-prohibitive for widespread use.

• Combination Therapies, integrating rosuvastatin with ezetimibe or PCSK9 inhibitors, are expanding due to increasing evidence of improved cardiovascular outcomes.

Regulatory and Reimbursement Trends

Increased reimbursement for high-intensity statins in developed markets amplifies demand. Regulatory agencies, such as the EMA and FDA, continue to endorse rosuvastatin as a first-line agent, especially in patients with familial hypercholesterolemia.

---

Market Projections

Short-term Outlook (Next 3 Years)

• Steady Growth in Emerging Markets: Rising CVD burden combined with increased healthcare infrastructure catalyzes expanding demand for affordable statins. Generic rosuvastatin sales are projected to grow at a compound annual growth rate (CAGR) of approximately 5%.

• Pipeline Innovations: Research into fixed-dose combination formulations may stimulate adherence and market share, especially among aging populations.

• COVID-19 Therapeutic Investigations: Ongoing studies could sway prescribing behaviors if rosuvastatin demonstrates significant benefits in inflammatory modulation or viral protection.

Mid to Long-term Forecast (3-10 Years)

• Shift Toward Personalized Therapy: Advances in pharmacogenomics will enable tailored rosuvastatin treatments, optimizing efficacy while minimizing risks like diabetes.

• Emergence of Novel Lipid-Lowering Agents: PCSK9 inhibitors and gene-editing therapies (e.g., base editing, CRISPR) threaten to disrupt the statin market if they prove cost-effective and scalable.

• Intellectual Property Extensions: Pending patents on formulations or delivery mechanisms could temporarily bolster market exclusivity.

• Regulatory Changes: Increasing emphasis on cost-effective, high-evidence medications will favor generic rosuvastatin, with potential policy incentives promoting adherence to guideline-directed therapy.

---

Key Takeaways

• Clinical Evidence reinforces rosuvastatin's central role in cardiovascular risk reduction, with ongoing trials exploring expanded therapeutic applications, including anti-inflammatory effects and COVID-19 management.

• Market Dynamics highlight a mature but evolving landscape characterized by intense generic competition, expanding penetration in emerging economies, and ongoing innovation-driven growth.

• Future Trends suggest a shift toward personalized medicine, increased utilization of combination therapies, and competitive pressures from novel lipid-lowering agents.

• Strategic Opportunities for stakeholders include investing in formulation innovations, participation in clinical research, and aligning with evolving regulatory and reimbursement policies.

---

FAQs

Q1: What distinguishes Crestor from other statins?
Crestor (rosuvastatin) exhibits higher potency and greater LDL-C reduction efficiency at lower doses compared to many statins, making it suitable for high-risk patients and those requiring aggressive lipid management.

Q2: How has patent expiry affected Crestor’s market?
Patent expiration in 2016 led to a surge in generic rosuvastatin availability, significantly reducing prices and increasing global access, especially in cost-sensitive markets.

Q3: Are there new clinical trials indicating additional benefits of rosuvastatin?
Yes. Ongoing research explores its anti-inflammatory properties, potential in viral disease management, and role in personalized therapy, with some early positive signals.

Q4: What are the main competitive threats to Crestor’s market share?
Emerging therapies like PCSK9 inhibitors and gene-editing approaches pose long-term threats, especially for patients at very high cardiovascular risk.

Q5: What regulatory trends could influence rosuvastatin use?
Regulatory agencies emphasize lowering healthcare costs via approval of generics, adherence to clinical guidelines, and incentivization of evidence-based therapies, all supporting continued use of rosuvastatin.

---

Conclusion

Crestor’s versatile clinical profile and established efficacy underpin its sustained global market presence. While challenges from generic competition and emerging therapies persist, ongoing clinical research and healthcare trends favor its continued relevance. Stakeholders poised to leverage innovations, alignment with regulatory policies, and expanding access will better position themselves in the evolving landscape of cardiovascular therapeutics.

---

Sources

[1] IMS Health. "Global Sales Data for Statins," 2022.
[2] ClinicalTrials.gov. List of rosuvastatin-related clinical trials, accessed January 2023.
[3] American College of Cardiology. "Statins and Cardiovascular Outcomes," 2021.
[4] EMA and FDA regulatory reports on rosuvastatin, 2022.